HL-217

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHL-217
Drug Alias NameKR-31831HL-217
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor subunit A inhibitorsPlatelet-derived growth factor subunit B inhibitors
TargetsPlatelet-derived growth factor subunit BPlatelet-derived growth factor subunit A
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKorea Research Institute Of Chemical Technology
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co LtdKorea Research Institute Of Chemical Technology
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A